EU tries to restrict vaccine exports to UK with emergency Brexit rules | Inquirer News

EU tries to restrict vaccine exports to UK with emergency Brexit rules

/ 05:37 AM January 30, 2021

FILE PHOTO: A vial of the Pfizer/BioNTech COVID-19 vaccine is seen ahead of being administered at the Royal Victoria Hospital, on the first day of the largest immunisation programme in the British history, in Belfast, Northern Ireland December 8, 2020. Liam McBurney/Pool via REUTERS//File Photo

LONDON — The European Union on Friday sought to restrict exports of COVID-19 vaccines to Northern Ireland by overriding a part of the post-Brexit deal with Britain, a steep escalation of the bloc’s battle to secure vaccine supplies.

Northern Ireland First Minister Arlene Foster described as “an incredible act of hostility” the decision by the EU to invoke Article 16 of the Northern Irish Protocol, which allows Britain or the EU to take unilateral action if there is an unexpected negative effect arising from the agreement.

Article continues after this advertisement

A spokesman for the British government said senior cabinet minister Michael Gove had expressed to the EU “concern over a lack of notification”, and said it would be “carefully considering next steps.”

FEATURED STORIES

The EU move is designed to prevent the open border between EU-member Ireland and Northern Ireland from acting as a backdoor for vaccine supplies into the United Kingdom.

It was not immediately clear if the move to invoke the article, set out in a document published on Friday, would come into effect immediately. A link to the document was no longer working at 2050 GMT.

Article continues after this advertisement

Article 16 was devised as a last resort to alleviate serious disruption to trade in Northern Ireland after Brexit.

Article continues after this advertisement

The EU, whose member states are far behind Israel, Britain and the United States in rolling out vaccines, is scrambling to get supplies just as the West’s biggest drugmakers slow deliveries to the bloc due to production problems.

Article continues after this advertisement

The British-Swedish drugmaker AstraZeneca has been caught in the crosshairs after it said last week it would fall short of delivering promised vaccines to the EU by March because of production problems in Belgium.

That has angered Brussels which has demanded to know why it cannot divert supplies from its British sites which have been producing millions of shots for British citizens.

Article continues after this advertisement

The European Commission has agreed a plan to control exports of vaccines from the bloc, including to Britain, arguing it needed to do so to ensure its own supplies.

The Commission said its move to invoke Article 16 was justified to “avert serious societal difficulties” in EU states due to a lack of vaccine supply, the document published on Friday said.

Britain has its own domestic supply chain in place for AstraZeneca’s shot, including rolling it out in Northern Ireland, but it imports Pfizer’s vaccine from a factory in Belgium.

Ireland’s Prime Minister Micheál Martin expressed concern to EU chief Ursula von der Leyen over the executive’s decision.

Northern Ireland’s Foster went further. “This is an incredible act of hostility,” she said.

“By triggering Article 16 in this manner, the European Union has once again shown it is prepared to use Northern Ireland when it suits their interests but in the most despicable manner – over the provision of a vaccine which is designed to save lives.”

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

Britain had threatened to trigger the Article 16 safeguard measures earlier in the month if there were “serious problems” in supplying supermarkets in Northern Ireland.

TAGS: AstraZeneca, Brexit

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.